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Abstract Inhibition of protein tyrosine phosphatases blocks 
tumor necrosis factor (TNF)-induced growth modulation and 
N F - K B activation, both mediated primarily through the p60 TNF 
receptor. How inhibition of the phosphatases affects the p60 
TNF receptor or the recently described receptor-associated 
serine/threonine kinase (p60TRAK) is not known. In this report, 
we show that this inhibition, when induced by pervanadate, 
caused the tyrosine phosphorylation of the cytoplasmic domain 
(CD) of the p60 receptor, as revealed by phosphoamino acid 
analysis. Furthermore, site-directed mutagenesis indicated that 
pervanadate specifically induced the phosphorylation of tyrosine-
331, which is located in the death domain of the TNF receptor, a 
domain to which p60TRAK binds. This tyrosine residue was also 
phosphorylated by purified, recombinant pp60Src in vitro. 
Inhibition of protein tyrosine phosphatases by pervanadate also 
led to the inactivation of p60TRAK. In contrast, okadaic acid, a 
specific inhibitor of protein serine/threonine phosphatase, in-
creased p60TRAK activity. Taken together, these results suggest 
that protein tyrosine phosphatases play an essential role in 
phosphorylation of the cytoplasmic domain of the TNF receptor 
and in regulation of the receptor-associated kinase, and this in 
turn may play a role in TNF-mediated growth modulation and 
N F - K B activation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The intracellular domains of both the p60 and p80 tumor 
necrosis factor (TNF) receptors lack motifs characteristic of 
protein tyrosine and serine/threonine kinases. Even so, several 
cellular proteins are phosphorylated both at serine/threonine 
and tyrosine residues upon engagement of the T N F receptor, 
including heat shock protein 27 [1], epidermal growth factor 
receptor [2], eukaryotic initiation factor 4E [3], IKBOC (the in-
hibitory subunit of N F - K B ) [4], insulin receptor substrate-1 [5 -
7], and the mitogen-activated protein kinase family (for refer-
ences see review [8]). The increased protein phosphorylation 
could be due to the reported activation of a variety of kinases 
and/or the inhibition of protein phosphatases (PPase) (for 
references see review [9]). 
By using the glutathione-S-transferase (GST) fusion protein 
system, we have previously demonstrated that two different 
serine/threonine protein kinases, p60TRAK and p80TRAK, 
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associate with the cytoplasmic domains of the p60 and p80 
T N F receptors, respectively [10-12]. Furthermore, a region of 
~ 54 residues (344-397) within the death domain of the p60 
receptor was found to be sufficient to associate with 
p60TRAK [12]. Additionally, a sequence residing near the 
C-terminus (residues 397^126), designated the kinase inhibi-
tory domain (KID), inhibits the binding of p 6 0 T R A K to the 
cytoplasmic domain [12]. 
While protein kinases are evident in the T N F signalling 
pathway, the role of PPases is less well understood. However, 
recent reports indicate that a protein tyrosine phosphatase 
(PTPase) is involved in TNF-mediated cellular responses in-
cluding cell growth inhibition and proliferation [13] and N F -
K B activation [14-16], all mediated through the p60 form of 
the T N F receptor [17,18]. Whether the p60 T N F receptor and 
the associated kinase (p60TRAK) are also regulated by tyro-
sine phosphorylation is not known. In the present study, we 
show that inhibition of PTPase causes a protein tyrosine kin-
ase to bind and phosphorylate tyrosine-331 which is located in 
the death domain of the T N F receptor. Additionally, PTPase 
inhibition results in inactivation of p 6 0 T R A K activity, and 
this may play a role in TNF-mediated growth modulat ion 
and N F - K B activation. 
2. Materials and methods 
2.1. Materials 
All reagents were obtained and prepared as previously described 
[10-12]. Purified, recombinant pp60Src was provided by Dr. R. Budde 
(The University of Texas M.D. Anderson Cancer Center). 
2.2. Construction of plasmids, expression and purification of fusion 
proteins and in vitro kinase assays 
All plasmids encoding GST-p60 cytoplasmic domain deletions have 
been described previously [10,11]. The GST-p60CD fusions used in 
these studies included A8, A12, and A15, which encompass residues 
324-397, 344-397, and 243-397, respectively [12]. The plasmids encod-
ing site-directed mutants of GST-p60A8T329A, GST-p60A8Y331F, and 
GST-p60A8T329A/Y331F were generated by polymerase chain reaction 
using pCMVXVBpL4-p60 [10] as the template and the following pri-
mers: A8T329A (y-BamUi): CTAAGAGGATCCACTGATGACC 
CCGCGGCGCTGTAC; A8Y331F and A8T329A/Y331F (5'-BamHI): 
CTAAGAGGATTCA CTGATGACCCCGCGG/ACGCTGTTCGC-
CGTGG; and for all A8 mutants Q'-Hindlll): TCTTAGAAGCTTT-
TAGCGGAGCACGCGTCCCAG. The PCR products were digested 
with BamHI-Hindlll and inserted into pGEX2TH. The creation of a 
Kspl site (underlined) in the primers made positive selection for the 
site-directed mutants possible. 
Expression of all GST fusion proteins from BL21 cells harboring 
the appropriate expression vector was induced with 0.5 mM isopro-
pylthiogalactoside at 15°C for 1 h and purified on glutathione-agarose 
beads as previously described [10,11]. Throughout this report, all fu-
sion proteins will be referred to by their deletion number (i.e., GST-
p60A8 will be referred to as p60A8). In vitro kinases assays were 
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Fig. 1. TNF activates p60TRAK in a time-dependent manner. U937 cells were treated with 10 ng/ml TNF for the indicated times and lysates 
were prepared. Cell lysates (300 ug) were affinity precipitated with p60fl and in vitro kinase assays were performed. The phosphorylation of 
p60fl was quantitated by a Phosphorimager and ImageQuant software. The fold-activation is presented as the deviation from the mean of three 
independent experiments. One such experiment is shown in the inset. 
performed as previously described [12]. Quantitation of phosphoryl-
ated proteins was performed by Phospholmager and ImageQuant 
software (Molecular Dynamics, Sunnyvale, CA). 
3. Results 
Previously, we reported that inhibition of PTPases blocks 
TNF-induced growth modulation [13] and N F - K B activation 
[15,16], both mediated primarily through the p60 form of the 
TNF receptor. In this report, we examined the effect of inhib-
ition of PTPases on the TNF receptor and the receptor-asso-
ciated kinase. 
3.1. p60TRAK is activated by TNF 
We first examined the activation of p60TRAK by treatment 
of cells with TNF. The full length cytoplasmic domain of the 
p60 (p60fi) TNF receptor (residues 205^-26) was fused to the 
C-terminus of GST and used to precipitate kinase activity 
form cytoplasmic extracts from U937 cells treated with 10 
ng/ml TNF for various times. The phosphorylation of p60fl 
was quantitated to measure the activity of p60TRAK. The 
results shown in Fig. 1 indicate that TNF activated 
p60TRAK activity in a time-dependent manner. The activa-
tion could be seen as early as 30 s, peaked at 5 min and 
remained elevated at 20 min. 
3.2. Inhibition of PTPases causes tyrosine phosphorylation of 
p60 TNF reporter 
To explore the effect of PTPases, we used the PTPase in-
hibitor pervanadate, which has been shown to block TNF-
induced N F - K B activation [14-16]. For these experiments, 
we also used constructs from the cytoplasmic region of the 
p60 receptor that comprised residues 324-397 (p60A8) and 
residues 344-397 (p60A12), both of which lack the KID and 
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Fig. 2. Inhibition of PTPases by pervanadate causes tyrosine phosphorylation of the TNF receptor. (A) Effect of pervanadate on p60A8 and 
p60A12. U937 cells were incubated with the indicated concentration of the inhibitor for 30 min at 37°C. Cell lysates were prepared, and affinity 
precipitated, and in vitro kinase assays performed using GST, p60A8 and p60A12. The samples were analyzed by 9% SDS-PAGE, and the dried 
gel exposed to X-ray film for 8 h at —70°C. (B) Phosphorylated TNF receptor (pp37) contains only phosphotyrosine. U937 cells were treated 
with pervanadate p60A8, and an in vitro kinase assay performed. The sample was subjected to SDS-PAGE and transferred to a PVDF mem-
brane. The radioactive band corresponding to pp37 was excised, and phosphoamino acid analysis was performed. The thin layer electrophoresis 
plate was exposed to Phosphorlmager, and the migration of phosphoamino acid standards was visualized by ninhydrin. (C) The amino acid se-
quence of the p60 cytoplasmic domain that differs between p60A8 and p60A12 is shown. 
bind p60TRAK in the absence of TNF [12]. U937 cells were 
treated with various concentrations of pervanadate for 30 
min, and the cell lysates prepared and affinity precipitated 
with either GST, p60A8, or p60A12 followed by in vitro kinase 
assays. Results in Fig. 2A show that increasing concentrations 
of pervanadate increased the phosphorylation of p60A8, 
which appeared as a slow migrating band at 37 kDa (pp37). 
Interestingly, pervanadate had no effect on the phosphoryla-
364 
tion of p60A12. The phosphoamino acid analysis of pp37, the 
phosphorylated p60A8, revealed that phosphorylation oc-
curred only on tyrosine (Fig. 2B). p60A8 contains a single 
tyrosine residue at position 331 (Y33) that is not present in 
p60A12. That pervanadate induced the tyrosine phosphoryla-
tion of p60A8 and not of p60A12 suggests that phosphoryla-
tion occurred at tyrosine-331 (Fig. 2C). If so, this would ex-
plain why pp37 was observed only in precipitates of p60A8, 
but not in that of p60A12 (Fig. 2A). Our results thus far 
suggest that inhibition of PTPase by pervanadate causes a 
protein tyrosine kinase (PTK), to bind and phosphorylate 
p60A8. 
3.3. Site-specific mutagenesis indicates that pervanadate 
induces phosphorylation of Tyr331 
To further confirm the site that undergoes phosphorylation 
by pervanadate, we replaced Tyr331 of p60A8 with phenylala-
nine by site-specific mutagenesis. We also made two addition-
al mutants; in one case we replaced Thr329 with alanine, and 
in the other we made a double mutant that contained substi-
tutions at both Thr329 and Tyr331 (Fig. 2C). Thr 329 was 
replaced with alanine to determine if the PTK involved is a 
dual-specificity kinase that can phosphorylate at both tyrosine 
and threonine residues. The three mutant fusion proteins and 
wild-type p60A8 were used in affinity precipitations of cell 
lysates from control and pervanadate-treated cells followed 
by in vitro kinase assays. The tyrosine-phosphorylated form 
of p60A8 (pp37) did not appear in pervanadate-treated cell 
extracts that had been affinity precipitated with p60A8Y331F 
or p60A8T329A/Y331F (Fig. 3, lanes 6 and 8), but it appeared 
in those extracts precipitated with either p60A8 (Fig. 3, lane 2) 
or p60A8T329A (Fig. 3, lane 4). Thus, these results further 
confirm that Tyr331 is the phosphoacceptor site for a PTK 
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Fig. 3. Site-specific mutagenesis implicates phosphorylation of 
Tyr331 of the p60 TNF receptor. U937 cells were incubated in the 
presence or absence of pervanadate (100 u,M, 30 min, 37°C). Cell ly-
sates were prepared, and affinity precipitations were performed with 
the indicated wild-type or mutant GST fusion proteins. In vitro kin-
ase assays were performed, the samples were analyzed by 8.5% 
SDS-PAGE, and the dried gel exposed to X-ray film for 3 h at 
—70°C. Relative mobilities for various molecules are indicated by 
the arrows. 
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Fig. 4. Tyr331 of the p60 cytoplasmic domain is phosphorylated by 
pp60Src in vitro. Approximately 10 |xg of GST, p60A8, and 
p60A8Y331F were first washed three times with kinase buffer. pp60Src 
(2.5 ng) was mixed with the indicated fusion proteins, and in vitro 
kinase assays performed in a volume of 20 JJ.1 containing 75 mM 
HEPES pH 8.0, 15 mM MgCl2, 0.2 mM ATP and 10 uCi [y-
32P]ATP for 30 min at 30°C. The reactions were stopped by addi-
tion of SDS-sample buffer, and the mixtures boiled and subjected to 
9% SDS-PAGE. The dried gel was exposed to X-ray film for 20 h 
at —70°C. The arrows represent the relative mobility of each fusion 
protein, and the asterisk indicates the tyrosine phosphorylated form 
of p60A8. 
that binds to the CD. Moreover, these results also suggest 
that this PTK is not likely to be a dual-specificity kinase. 
3.4. pp60Slc phosphorylates Tyr331 of the p60 cytoplasmic 
domain in vitro 
To determine the potential PTK responsible for the phos-
phorylation of the p60CD in pervanadate-treated cells, we 
tested the ability of several known PTKs to phosphorylate 
Tyr331 in vitro. Of those tested (pp60Src, Csk, FGFr, Abl 
and YES), only pp60Src phosphorylated Tyr331 (Fig. 4). 
pp60Src did not phosphorylate GST nor p60A8Y331F. 
3.5. Pervanadate inhibits p60TRAK-mediated phosphorylation 
of pp55 and pp58 
We have previously shown that p60TRAK, which associ-
ates with the TNF receptor, phosphorylates two proteins of 
approximately 55 and 58 kDa (pp55 and pp58). These pro-
teins were not the endogenous receptor as indicated by west-
ern blot with anti-p60 receptor antibody. Quantitation of the 
experiment described in Fig. 2A revealed that the phosphoryl-
ation of pp58 and pp55 decreased with increasing dose of 
pervanadate, thus indicating that inhibition of a PTPase leads 
to the inhibition of p60TRAK activity. These results are con-
sistent with that described in Fig. 3 (compare lanes 1, 3, 5 and 
7 with 2, 4, 6, and 8). 
3.6. Okadaic acid stimulates p60TRAK-mediated 
phosphorylation of pp55 and pp58 
We also compared the effect of pervanadate (PTPase inhib-
itor) with okadaic acid, a specific inhibitor of serine/threonine 
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Fig. 5. Okadaic acid increases the activity of p60TRAK. (A) Okadaic acid treatment of cells increases p60TRAK activity. U937 cells were incu-
bated with the indicated concentration of okadaic acid for 30 min at 37°C. Cell lysates were prepared and affinity precipitated, and in vitro 
kinase assays performed using GST, p60A8 and p60A12. The molecular mass standards are indicated in kDa. (B) Stimulation of p60TRAK ac-
tivity by okadaic acid is reversible. U937 cells were incubated in the absence or presence of 0.6 uM okadaic acid for 30 min at 37°C. Cell ly-
sates were prepared and used for affinity precipitation of p60TRAK by p60A8. These precipitates were washed first with lysis buffer and then 
with the phosphatase buffer (50 mM HEPES, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol). In separate tubes, a source of cytosolic protein 
phosphatases was prepared from 5X106 U937 cells lysed in 600 |xl in the presence or absence of protein phosphatase inhibitors (10 mM NaF, 
2 mM orthovanadate, 0.6 U.M okadaic acid) (PPi). Phosphatase assays were performed by the addition of 10 ul of these extracts with the pre-
cipitated p60TRAK as indicated and incubated at room temperature for 20 min. These mixtures were then washed sequentially in lysis buffer 
and kinase buffer. In vitro kinases assays were then performed and the samples were analyzed by 8.5% SDS-PAGE and quantitated on a Phos-
phorlmager. 
phosphatase type 2A and type 1 [19], on p60TRAK activity. p60A8, or p60A12 followed by in vitro kinase assays. In con-
Okadaic acid is also known to mimic some of the effects of trast to pervanadate, okadaic acid treatment caused a dose-
TNF [4,20]. U937 cells were treated with increasing concen- dependent increase in phosphorylation of p60A8, p60A12, and 
trations of okadaic acid for 30 min, and then affinity precip- the two associated proteins pp58 and pp55 (Fig. 5A). This 
itations of cell lysates were performed with either GST, increase was not due to a direct effect of okadaic acid on 
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Fig. 6. Histone HI phosphorylation by p60TRAK is also regulated by phosphatase inhibitors. U937 cells were left untreated (C) or treated 
with pervanadate (PV) (100 itM, 30 min, 37°C) or okadaic acid (OA) (600 nM, 30 min, 37°C). Cells lysates were prepared and affinity precipi-
tated with GST or p60A15 (A15), and in vitro kinase assays performed with 5 ug histone HI. The phosphorylation of histone HI and pp58/ 
pp55 were quantitated by a Phosphorimager and ImageQuant software and presented as percent of control. Similar results were obtained in 
three independent experiments. 
p60TRAK because its addition in the kinase assay had no 
effect (data not shown). 
3.7. Okadaic acid and pervanadate modulate p60TRAK by 
phosphorylation 
The activation of p60TRAK by okadaic acid could be due 
to an increase in either p60TRAK binding to the p60CD or in 
serine/threonine phosphorylation of p60TRAK. To distin-
guish between these two possibilities, we isolated p60TRAK 
from untreated or okadaic acid-treated cells and then assayed 
for its activity before and after exposure to cellular PPase. 
Okadaic acid-induced activation of p60TRAK activity (i.e., 
Fig. 5B, compare lanes 1 and 2) could be reversed to control 
level by cellular PPase (compare lanes 3 and 4), and the in-
hibition of the latter by phosphatase inhibitor (PPi) reversed 
the effect of okadaic acid (compare lanes 2 and 6). The quan-
titation of lanes 1 and 2 indicates that OA increases phos-
phorylation of p60A8 and pp58/55 by 8.4-folds and 5.5-folds, 
respectively. Similarly, quantitation of lanes 5 and 6 indicates 
that OA increases phosphorylation of p60A8 and pp58/55 by 
3.4-folds and 1.5-folds, respectively. Although cell extracts 
(cellular PPase) increase the overall phosphorylation but OA 
has no additional effect (3.1 vs. 3.6 for p60A8 and 3.4 vs. 3.7 
for pp58/55). Why degree of phosphorylation of p60A8 is 
different from that of pp55/58, is not clear. The difference 
may lie in the number of phosphorylation sites present in 
each. Taken together, these results suggest that okadaic acid 
treatment increased p60TRAK activity not by increasing its 
binding to p60CD but by enhancing its phosphorylation at 
serine/threonine. 
Although mutation of Tyr331 altered its phosphorylation by 
the associated PTK, none of the mutations affected binding of 
p60TRAK to p60CD since the extent of its phosphorylation 
was similar (Fig. 3, compare lanes 1, 3, 5, and 7 for p60A8). 
To further determine that it is not the binding but the perva-
nadate treatment that inactivates p60TRAK, we examined the 
phosphorylation of histone HI by p60TRAK from untreated, 
pervanadate- or okadaic acid-treated cells. Since histone HI 
exhibits the same mobility as p60A8 on SDS-polyacrylamide 
gels, we used p60A15 (residues 243-397), which migrates at 
~ 50 kDa for the affinity precipitations. Previous experiments 
showed no difference in the ability of p60A8 or p60A15 to 
precipitate p60TRAK [12]. Quantitation of histone HI and 
of pp58/55 revealed that pervanadate inhibited their phos-
phorylation by 44% and 33%, respectively, and okadaic acid 
stimulated it by 490% and 940%, respectively (Fig. 6). Thus, 
p60TRAK appears to be inhibited by tyrosine phosphoryla-
tion and activated by serine/threonine phosphorylation. 
4. Discussion 
The results presented in this report demonstrate that inhib-
ition of PTPases by pervanadate causes the phosphorylation 
of the tyrosine residue at position 331 in the cytoplasmic 
domain of the p60 TNF receptor. Furthermore, we show 
that p60TRAK is inactivated by pervanadate and stimulated 
by okadaic acid. This is the first report to show tyrosine 
phosphorylation of the TNF receptor. The cytoplasmic do-
main of the p60 TNF receptor contains seven tyrosine resi-
dues, whereas that of the p80 form of the receptor contains 
none. Of the seven tyrosine residues in the p60CD, only two 
(position 331 and 372) are located in the death domain of the 
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receptor, the region responsible for recruitment of proteins 
involved in TNF signalling, including cytotoxicity and NF-
KB activation (for references see [21]). 
Our results indicate that inhibition of PTPase leads to phos-
phorylation of Tyr331 and to inhibition of TNF cell signalling 
as reported earlier [14—17]. How Tyr331 phosphorylation 
might lead to inhibition of cell signalling is not clear. It is 
possible, however, that Tyr331 phosphorylation affects the re-
cruitment by the receptor of the TNF receptor associated 
death domain (TRADD) which is necessary for N F - K B acti-
vation and growth modulation [21]. This possibility is similar 
to cellular signalling by other growth factors where associa-
tion and dissociation of signal-transducing proteins are regu-
lated by tyrosine phosphorylation and dephosphorylation 
([22] and references therein). 
Our results also suggest that tyrosine phosphorylation leads 
to a decrease and serine/threonine phosphorylation to an in-
creases in the activity of p60TRAK. This is a situation anal-
ogous to cyclin-dependent kinase, whose activity decreases by 
specific tyrosine phosphorylation and increases by serine/ 
threonine phosphorylation ([23] and other references therein). 
The type of PTK involved in phosphorylation of the p60 TNF 
receptor is not clear. Our results, however, show that among 
several PTKs tested, pp60Src induces optimal phosphorylation 
of Tyr331. These results are consistent with our previous ob-
servations that overexpression of cells with pp60Src leads to 
resistance to the cytotoxic effects of TNF [24]. Therefore, it is 
possible that pp60Src is activated on inhibition of PTPase, thus 
leading to TNF receptor phosphorylation and resistance to 
ligand-induced cellular responses. Overall our results pre-
sented here show that inhibition of PTPase alters the phos-
phorylation state of the p60 receptor and modulates the re-
ceptor-associated kinase. These changes may play a role in 
TNF-induced N F - K B activation and growth modulation. 
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